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Abstract 
 
Background - The purpose of this study was to determine the extent to 
which summary index scores from the short form Parkinson’s Disease 
Questionnaire (PDQ-8) replicate those from the parent form (PDQ-39) in a 
longitudinal study. 
Methods – Longitudinal data gained from the PD-MED trial were examined 
(n=1867), to determine the extent the PDQ-8 replicates results from the 
PDQ-39 at baseline and follow up. The sensitivity to change of the PDQ-8 was 
also compared with that of the PDQ-39. Finally, results on the two measures 
were compared with those from the Hoehn and Yahr (HY) clinical staging 
scale. 
Results – Results of the Single Index summary score gained from the PDQ-8  
were found to closely replicate those gained from the PDQ-39 at each of the 
three time points. Furthermore at each time point the intraclass correlation 
coefficient between the two measures was very high (ICC range 0.93 – 0.96). 
Similarly, the two measures gave very similar accounts of change (e.g. from 
baseline to follow up at one year effect sizes were 0.18 for the single index 
calculated using the PDQ-39, and 0.09 when calculated using the PDQ-8). 
Similar levels of correlation were found between the two indices when 
correlated with the HY scale. 
Conclusions – The PDQ-8 closely replicates results gained from the PDQ-39 
when calculating single indices. In instances where a single summary score of 
the impact of PD on self-reported quality of life is needed, it is likely the PDQ-
8 will provide reliable and accurate information. 
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Introduction 
 
Patient reported outcome measures (PROs) play an increasingly important 
role in the evaluation of medical care [1] and have been advocated as 
potentially important end–points in clinical trials [2]. Traditionally, neurologists 
have chosen to develop rating scales for Parkinson’s disease (PD) based on 
clinical assessment [3]  and which classically focus on neurological symptoms 
and physical impairment [4,5,6,7]. However, typically such instruments fail to 
address the full impact of the illness upon subjectively assessed quality of life 
(QoL) of patients [8]. Consequently, a number of PD specific PROs have been 
developed [9] to capture the overall impact of PD on health-related quality of 
life with the most widely used and validated being the Parkinson’s Disease 
Questionnaire (PDQ-39) [10,11,12].  Use of the instrument has been 
recommended in a number of critical reviews of competing PROs in PD 
[13,14,15].  
 
The PDQ-39 is a 39 item self-report questionnaire which measures eight 
dimensions of health. The instrument was developed on the basis of 
interviews with people with Parkinson’s (PwP) and consequently measures 
areas of concern which are of particular salience to this patient group. 
Furthermore, scores from the eight dimensions can be aggregated onto the 
same metric to provide a single index of the overall impact of PD on self-
reported health status [16]. Such summary indices are useful in giving a 
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global score of the impact of disease, and are useful in trials by reducing the 
risk of chance findings due to multiple comparisons across dimensions [17].  
Further research developed a shorter form PDQ which can be used to create 
the single index. The PDQ-8 [18] was developed by selecting the item from 
each dimension most highly correlated with the corrected dimension total. 
The resulting PDQ-8 summary index (PDQ-8-SI) has been shown to produce, 
in cross sectional and test-retest studies, results that are encouragingly 
similar to the PDQ-39 summary index (PDQ-39-SI) [19]. However, to date 
limited information has been available concerning the sensitivity to change of 
the PDQ-8 in relation to the PDQ-39 over time. This is an important issue 
when selecting and using instruments in evaluative studies [2]. Consequently, 
the aim of this study was to compare data generated from the PDQ-8-SI and 
the PDQ-39-SI over time, in a longitudinal study.  
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Methods 
Data reported here are from PD-MED, a randomised clinical trial evaluating 
the comparative clinical and cost-effectiveness of different classes of drugs in 
PwP. Patients were categorised as receiving treatment for ‘either’ early or 
‘late’ PD. Those classified as ‘late’ were those whose symptoms were no 
longer controlled by their first class of treatment. The primary outcome 
measure for the trial was health-related QoL as measured by the PDQ-39. In 
this paper data is not broken down by treatment arm but is broken down by 
‘early’/’late’ categories. Full details of the trial design and results are published 
elsewhere [20]. 
The trial was awarded Multi-Centre Research Ethics Committee (MREC) 
approval and Clinical Trials Authorisation from the Medicines and Healthcare 
Regulatory Authority (MHRA). All respondents gave informed written consent 
to participate in the study. 
 
Participants: PwP from over 80 neurology and care of the elderly units 
across the United Kingdom participated in clinic-based tests and postal 
evaluations via questionnaires. PD MED recruited 2120 patients - 1620 early 
and 500 later patients. 1366 (64.4%) of PwP in PD MED were male and 754 
(36.6%) female. In this study only participants who had complete data to 
enable calculation on the PDQ-8-SI and PDQ-39-SI are included in the 
analyses. Consequently, 1434 (88.51%) PD MED early and 433 (86.6%) late 
respondents are reported. The mean age at recruitment into the study was 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 7
70.46 years (range 27 to 94), and mean disease duration was 11.22 years 
(range 4.9 to 38.6 years). 
 
Materials: Three validated measures form the basis of the analyses reported 
here: 
 The PDQ-39 [11]: As previously introduced, a 39 item self-report 
questionnaire which measures eight dimensions of health, namely 
mobility, activities of daily living, emotional well-being, stigma, social 
support, cognition, communication, and bodily discomfort. Dimension 
scores are coded on a scale of 0 (perfect health as assessed by the 
measure) to 100 (worst health as assessed by the measure). A number of 
studies indicate that the instrument possesses sound levels of reliability, 
validity and responsiveness [10,11,12,21,22,23]. The PDQ-39-SI is 
calculated by summing the eight dimensions of the instrument and 
standardising the score on a scale of 0 to 100. 
 The PDQ-8 [18]: As previously introduced, an 8 item self-report 
questionnaire derived from its parent questionnaire, the PDQ-39 [11]. The 
PDQ-8 has been shown to exhibit appropriate levels of reliability, validity 
and responsiveness [12,18,19]. The PDQ-8-SI is calculated by summing 
the eight items of the instrument and standardising the score on a scale of 
0 to 100. It should be stressed that the PDQ-8 was not administered as a 
separate instrument in this study. Rather, it was calculated from PDQ-39 
data which may have influenced the manner in which items were 
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completed. It is, however, standard practice to assess short form 
instruments in this way [18,24,25,26]. All PDQ data was collected by paper 
and pen completion via postal surveys. 
 The modified Hoehn and Yahr (HY) staging scale [4, 27]: A widely used 
clinical measure of disability in PwP, the HY scale classifies seven stages of 
disease which are rated by a clinician. The scale is regarded as fulfilling 
reasonable criteria for reliability and validity [26]. All HY data was obtained 
in clinic visits. 
 
Statistical analysis: Trial data from baseline and three follow up points 
(one, two and three years) were subject to analysis. The data are analysed 
broken down by ‘early’/’late’ category, but not analysed by treatment arm. 
Descriptive statistics (mean, standard deviation (SD), median, minimum, 
maximum) were calculated for the P Q-39 and PDQ-8 single indices. 
Concordance between the two indices was evaluated by the intraclass 
correlation coefficient (ICC; two-way mixed average, absolute agreement) in 
conjunction with the calculation of 95% confidence intervals (CIs). Mean 
change scores were calculated for the summary index of the PDQ-39 and the 
PDQ-8. Effect sizes, i.e. change in score in relation to its SD [28] were also 
calculated for the summary index on both the PDQ-39 and PDQ-8. Scores on 
the two PDQ indices were correlated with the HY scale cross-sectionally, using 
Spearman’s rho. Data was analysed using SPSS Version 19. 
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Results 
 
Tables 1 and 2 report scores on the PDQ-39-SI and the PDQ-8-SI, broken 
down by ‘early’ and ’late’ PD respectively, for those respondents who 
completed all items on the PDQ-39 which enables calculation of the summary 
scores. No meaningful differences were found between scores on the PDQ-
39-SI and the PDQ-8-SI at any of the time points. Indeed, mean differences 
between the two scores were very small, ranging from 0.6 to 1.1 points. ICCs 
suggested that the results for both ‘early’ and ‘late’ respondents from both 
measures were remarkably similar at each time point with ICCs ranging from 
0.93 (95% CI 0.92 – 0.94) to 0.96 (95% CI 0.96 – 0.97). Change scores on 
the two versions of the PDQ were calculated and ICCs calculated between 
them and ranged from 0.89 (95% CIs 0.88 – 0.90) to 0.90 (95% CIs 0.89-
0.91). 
 
The sensitivity to change of the PDQ-8-SI was compared with that of the 
PDQ-39-SI. Mean change scores over time were found to be similar and found 
to be highly correlated (ICCs ranged from 0.89 to 0.90). Table 3 reports mean 
changes between baseline and follow up at one, two and three years. Effect 
sizes were also calculated, and indicate the PDQ-8-SI replicates the results of 
the parent form. 
 
Scores from respondents assessed by a clinician on the Hoehn and Yahr scale 
(H&Y) are presented in Table 4. PDQ-39-SI and PDQ-8-SI scores were 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 10
correlated with this score at the three follow up points. Both versions of the 
PDQ correlated moderately, and, importantly, reflected similar levels of 
magnitude, with the H&Y scale at all follow up time points. At year one the 
H&Y correlation with the PDQ-39-SI was 0.27, n=1551, p<0.001 and, for the 
PDQ-8-SI it was rho=0.26, n=1551, p<0.001, at year two the correlations 
were rho=0.31, n=1442, p<0.001 and 0.33, n=1442, p<0.001 respectively, 
and at year 3 the correlations were rho=0.33, n=1181, p<0’.001 and 0.32, 
n=1181, p<0.001 respectively. 
 
Discussion 
Previously reported research using higher order factor analyses of the eight 
domains of the PDQ-39 across countries supports the derivation of the PDQ-
39-SI and PDQ-8-SI [19,29]. In the current study comparison is made of the 
two summary indices in order to investigate how closely they replicate one 
another. Data reported from PD-MED is for baseline and follow up at one, two 
and three years, which provide sufficient data to assess the operating 
characteristics of both indices cross-sectionally and over time.  
 
Mean and median scores for the two measures were strikingly similar. 
Results, when broken down by PD ‘Early’ or ‘Late’ indicated that the operating 
characteristics of the measures were consistent. Thus, PDQ-8-SI scores were 
highly significantly correlated with those of the PDQ-39-SI for both ‘early’ and 
‘late’ respondents’. The two instruments also provided remarkably similar 
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pictures of change over time. The construct validity of the two measures was 
assessed by comparing results with a clinical assessment of disease status. 
Correlations between the two index scores and the HY scale were virtually 
identical.  
 
The results presented suggest that the PDQ-8 can replicate results gained 
from the PDQ-39 for the single index score. It can do this with considerable 
economy, in terms of time needed to complete, and with considerable 
accuracy at the level of the group. Such results might be of significant interest 
where a brief measure is required due to time constraints or concerns 
regarding respondent burden, something of particular concern when 
assessing those in the more advanced stages of PD. Where this is the case 
investigators can, with confidence, incorporate the PDQ-8 as a means of 
capturing the impact of PD over time in, for example, clinical trials. It must be 
stressed, however, that where a detailed profile of disease impact on different 
dimensions is required the PDQ-39 should remain the instrument of choice. 
 
Copies of the instruments, and a user manual, are available from the authors. 
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Table Legends: 
 
Table 1: Descriptive statistics for ‘early PD’ respondents for which both the PDQ-39-SI and the PDQ-
8-SI could be calculated at baseline and follow up at years one, two and three. 
 
Table 2: Descriptive statistics for ‘late PD’ respondents for which both the PDQ-39-SI and the PDQ-8-
SI could be calculated at baseline and follow up at years one, two and three. 
 
Table 3: Mean (SD) median differences and effect size calculations for the PDQ-39-SI and PDQ-8-SI 
from baseline to years 1, 2 and 3. 
 
Table 4: Hoehn and Yahr staging scale frequencies. 
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Table 1: Descriptive statistics for ‘early PD’ respondents for which both the PDQ-39-SI and the PDQ-
8-SI could be calculated at baseline and follow up at years one, two and three. 
_______________________________________________________________________________ 
   n Mean   SD Median     Min        25th         75th              Max 
        percentile       percentile  
________________________________________________________________________________ 
Baseline 
PDQ-39-SI  1434 23.69   21.22    21.22     0.00       12.70       32.20        80.63 
PDQ-8-SI   24.53   16.95    21.87     0.00       12.50       34.38        84.38 
Difference   -0.84   5.73    -0.44    -21.56     -4.34        2.97           16.98 
Follow-up Year 1 
PDQ-39-SI  1237 25.28   16.07     22.34     0.00       12.63       34.66       82.19 
PDQ-8 -SI   25.90   17.89    21.88      0.00         12.50       37.50      93.75 
Difference   -0.62   5.00      -0.52     -27.29       -3.65        2.60        22.03 
Follow-up Year 2 
PDQ-39-SI  1097 27.73    16.85    25.16     0.00        14.66       38.33      90.36 
PDQ-8 -SI   28.83    18.97    25.00     0.00         12.50      40.63      100 
Difference   -1.09    5.17     -0.83      -31.88      -4.17        2.14        16.04 
Follow-up Year 3 
PDQ-39-SI  941 29.29    17.41    25.36     0.00          15.76        39.69    97.92 
PDQ-8 -SI   30.38    19.57    25.00     0.00          15.63        43.75    100 
Difference   -1.10    5.13      -0.78     -21.93       -4.22         2.31       14.48 
______________________________________________________________________________ 
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Table 2: Descriptive statistics for ‘late PD’ respondents for which both the PDQ-39-SI and the PDQ-8-
SI could be calculated at baseline and follow up at years one, two and three. 
________________________________________________________________________________ 
   n Mean   SD Median     Min        25th        75th              Max 
         percentile    percentile 
_________________________________________________________________________________ 
Baseline 
PDQ-39-SI   433 23.57   14.05    21.98     0.00         12.53      31.22        81.72 
PDQ-8-SI   24.26   16.83    21.88     0.00          10.94     34.38        84.38 
Difference   -0.68    5.95    -0.21    --20.16       -3.84       2.97        17.50 
Follow-up Year 1 
PDQ-39-SI   388 24.87   16.36     22.01     0.00         11.60       34.99      82.67 
PDQ-8 -SI   25.28   18.28    21.88      0.00           12.50       34.76     90.63 
Difference   -0.42    4.88     -0.03      -15.83        -3.68         2.86       15.36 
Follow-up Year 2 
PDQ-39-SI   358 26.53    16.55    23.80     0.00        13.91        36.26       80.78 
PDQ-8 -SI   27.39    18.41    25.00     0.00         12.50       37.50       84.38 
Difference   -0.87    5.11     -0.76      -14.06      -4.39         2.63        17.40 
Follow-up Year 3 
PDQ-39-SI  293 27.35    16.20    26.61     0.83         14.90        15.63     89.94 
PDQ-8 -SI   28.62    18.59    28.13     0.00         36.46         40.63     93.75 
Difference   -1.28     4.92     -0.94     -15.83     -4.32            2.08       10.94 
______________________________________________________________________________ 
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Table 3: Mean (SD) median differences and effect size calculations for the PDQ-39-SI and PDQ-8-SI 
from baseline to years 1, 2 and 3. 
 
_________________________________________________________________________________ 
     n mean   (SD)        95% CI   Median       25
th
        75
th
         Effect 
    percentile  percentile      size 
__________________________________________________________________________________ 
Baseline-Year 1 
PDQ-39-SI  1459 1.99 (11.00)       1.42-2.73       1.51     -1.84      8.28          0.18 
PDQ-8-SI   1.16 (12.84)       0.50-1.82       -1.35     -8.85      6.41          0.09 
 
Baseline-Year 2 
PDQ-39-SI  1322 5.02 (15.15)       4.20-5.84       3.64     -11.41     2.51        0.33 
PDQ-8-SI   4.77 (12.40)       4.10-5.44       3.13     -12.50     3.13        0.38 
 
Baseline-Year 3 
PDQ-39-SI  1113 7.12 (13.35)       6.33-7.91       5.68     -14.30      1.54       0.53 
PDQ-8-SI   7.55 (16.36)       6.59-8.51       6.25     -15.63      3.13       0.46 
 
__________________________________________________________________________________ 
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Table 4: Hoehn and Yahr staging scale frequencies 
_________________________________________________________________ 
                   1             1.5         2             2.5         3             4          5 
_________________________________________________________________ 
Year 1  274         222         536          258         223         33         6 
  17.6%     14.4%     34.5%      16.6%     4.4%      2.1%     0.4% 
 
Year 2  171         161         401          243         232         41         11 
  13.6%     12.8%     31.8%      19.3%     18.4%     3.3%     0.9% 
 
Year 3  98          134         345          212         259         56         14 
  8.8%      12.0%     30.9%      19.0%     23.2%     5.0%     1.3% 
 
_____________________________________________________________________ 
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Highlights 
The PDQ-39 is the most widely used patient reported outcome measure (PRO) 
in trials for treatments in Parkinson’s Disease. 
A shorter form of the measure has been developed (the PDQ-8) which can 
provide the Summary Index of the parent form. 
This study reports results from a longitudinal study that indicates the PDQ-8 
Summary Index closely replicated results of the parent form. 
This information is likely to be used for those planning to use the PDQ 
Summary Index as a primary or secondary in trials and other longitudinal 
studies. 
